ERBB2 and breast cancer: In a randomized phase III PADA-1 trial (NCT03079011), patients with ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced BC receiving first-line AI and CDK4/6i therapy were recruited and monitored for rising blood ESR1 (bESR1) mutations (17).